Abstract
Ovarian cancer represents the 4-th reason of cancer related death in women, the majority of patients being diagnosed in advanced stages of the disease, (III-IV). The loco-regional advanced ovarian cancer should be considered a chronic disease, with multiple evolutionary relapses and where the adjuvant treatment is mandatory.The treatment of the disease is multidisciplinary and the oncologist is the centerpiece.
Celsius.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab / administration & dosage
-
Biomarkers, Tumor / blood*
-
Chemotherapy, Adjuvant / methods
-
Early Detection of Cancer
-
Evidence-Based Medicine
-
Female
-
Genes, BRCA1*
-
Genes, BRCA2*
-
Humans
-
Mutation*
-
Ovarian Neoplasms* / blood
-
Ovarian Neoplasms* / diagnosis
-
Ovarian Neoplasms* / drug therapy
-
Ovarian Neoplasms* / genetics
-
Ovarian Neoplasms* / mortality
-
Phthalazines / administration & dosage
-
Piperazines / administration & dosage
-
Treatment Outcome
Substances
-
Biomarkers, Tumor
-
Phthalazines
-
Piperazines
-
Bevacizumab
-
olaparib